Acute lower respiratory infections resulting from respiratory syncytial virus (RSV) was the global cause of more than 100,000 mortalities of children aged five or less, writes Danish media Medicinsk Tidsskrift (”Medical Times”) citing a new study published in The Lancet.
”RSV is the leading cause of acute lower respiratory infections in small children. Our updated estimations reveal that children six months of age and younger are particularly vulnerable. Having been shielded by Covid-19 restrictions, this group has not been exposed to RSV previously and thus has no immunity,” says one of the study’s researches, Haris Nair from the University of Edinburgh, while pointing out that there are a number of RSV vaccines in development, which certain groups, particularly pregnant people in low and middle-income countries, should be considered for.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Genmab to submit cancer candidate epcoritamab to the FDA before year-end
The US Food and Drug Administration will receive a marketing authorization application from Genmab and partner Abbvie in the second half of this year.
Novo Nordisk denied general conditional reimbursement for Wegovy in Denmark – again
The Danish Medicines Agency has been told for the second time that the price of the obesity drug is not in line with the effect it provides.
Bavarian Nordic is working with EMA on monkeypox vaccine label expansion
Bavarian Nordic’s smallpox vaccine Imvanex has previously been used off-label to protect close contacts from monkeypox in several countries. The Danish vaccine firm is now working with the EMA to expand the label in an ”accelerated process.”
Coloplast's climate goals approved by international initiative
The Science Based Targets initiative has approved Coloplast’s carbon emission reduction goals.
Top news from MedWatch this week
Miss anything?
Principal Laboratory Technologist Medicinal Chemistry 
Commercial Market Data Manager 
Chair of the Board 
Open position for a Clinical Trial Manager to join our team at Nykode! 
KLIFO is looking for a Clinical Trial Assistant for our office in Glostrup, Lund or Münich 
Senior Toxicologist 
Project Managers keep all of us healthy 
Senior Teaching Fellow for the BioMedical Design Novo Nordisk Foundation Fellowship Program 
Regulatory Affairs Manager - Maternity Cover 
Global Product Manager - ENT 
Director Regulatory Affairs